BioNotebook: Four deal updates, a venture funding round and a milestone fee
This article was originally published in Scrip
Executive Summary
TG Therapeutics signs a study partner; Editas completes patent deals; J&J adds two collaborators; Allena raises $25m Series B; and CTI earns Trisenox milestone fee.
You may also be interested in...
BIO Notebook, Day 4: Annual Convention Winds Down With Oncology In The Spotlight
Oncology was top of mind for Scrip on the final day of the BIO International Convention in San Diego, including a next-generation cancer drug panel discussion and interviews with novel therapeutic developers. A day earlier, we spoke with Merck & Co about deals related to Keytruda and beyond.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.